Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Ping An Healthcare and Technology Company (PIAHY) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Ping An Healthcare and Technology Company $1.03, price $1.47, upside -29.9%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
PA
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
Ping An Healthcare and Technology Company
PIAHY · USOvervalued / MonitorQuality is not strong enough to offset the price risk.
!Fair value $1.03 · Overvalued (−29.9%)
!Quality 52/100
!Weak Growth (revenue 5y −5.0 %/yr)
!Thin margins · 6.9% net margin (TTM)
✓generates free cash flow
!Narrow moat 36/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $1.31 – $15.34 · fair‑value band $0.8600 – $1.35 · the $1.47 price screens above the $1.03 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China.
Show more
Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China. It offers online diagnosis and treatment, online consultation services, audio and video consultations, standardized healthcare service packages, health check-ups, genetic testing, concierge services, health management services, smart device sales, and consulting services. The company also provides online consultation, hospital referral and appointment, inpatient arrangement, and second opinion services; prepaid cards and health check-up services. The company online consultation, hospital referral, inpatient arrangement, second opinion services, electronic prescriptions, health management, prepaid packages for healthcare products and services, provision of products in the Group's health mall, advertising services, and consulting services, as well as operates an insurance agency. In addition it is involved in the integrated finance business. The company was incorporated in 2014 and is headquartered in Shanghai, China. Ping An Healthcare and Technology Company Limited operates as a subsidiary of Glorious Peace Limited.
Stock analysis
Ping An Healthcare and Technology Company (PIAHY) currently trades at $1.47, while our model-based Fair Value estimate is $1.03, 29.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of $8.07 per share, and 8 of the 26 models we run sit above the $1.47 price.
Bear case: the Economic Profit group reads lowest at $0.5800, and 18 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $0.8600 (bear) to $1.35 (bull), the price of $1.47 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Ping An Healthcare and Technology Company reported revenue of 5.3B CNY in FY2025 versus 7.3B CNY in FY2021, a compound −7.7%/yr. Reported net income was 369M CNY in FY2025.
Key figures
Market cap $3.2B · P/E ratio 60.0 · P/S ratio 4.16 · EPS (TTM) $0.0500 · Net margin 6.9% · Return on equity 5.6% · Return on assets (EBIT) −3.2% · Operating margin 4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 70% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −30%, PIAHY screens richer than that median.
Fair Value models
Bear $0.8600
Fair Value $1.03
Bull $1.35
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0378 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$1.02
$1.57
$2.49
77
Residual Income
$1.03
$1.02
$1.05
76
Growth DCF
$1.01
$1.50
$2.30
75
All 26 models by family
DCF Models
FCF DCF
$1.02
$1.57
$2.49
77
Owner Earnings
$1.04
$1.60
$2.56
72
5Y Revenue Exit
$0.7200
$0.9300
$1.20
71
5Y EBITDA Exit
$0.8000
$1.09
$1.45
73
5Y P/E Exit
$1.09
$1.71
$2.42
68
10Y Revenue Exit
$0.8100
$1.04
$1.38
65
10Y EBITDA Exit
$0.8700
$1.16
$1.59
66
10Y P/E Exit
$1.06
$1.61
$2.39
61
Earnings-Based
Graham-Dodd
$0.3500
$1.69
$2.33
64
Lynch FV
$0.4500
$0.6500
$0.8400
61
PEG = 1.0
$0.4500
$0.6500
$0.8400
57
EPV
$0.5500
$0.5800
$0.6100
70
Dividend Discount
Gordon GGM
$4.69
$9.34
$14.14
67
DDM Multi-Stage
$4.69
$8.07
$9.86
67
Multiples
P/E Multiple
$0.8600
$1.14
$1.43
63
P/S Multiple
$0.6600
$0.8800
$1.10
58
P/B Multiple
$0.6600
$0.8800
$1.10
55
EV/EBIT
$0.6600
$0.7700
$0.8800
63
EV/EBITDA
$0.7100
$0.8400
$0.9600
64
EV/Revenue
$0.5700
$0.6700
$0.7700
52
Asset-Based
NCAV (Graham)
$0.7000
$0.9300
$1.39
51
Growth DCF
Growth DCF
$1.01
$1.50
$2.30
75
Rev-Margin DCF
$0.7200
$0.9300
$1.21
71
Economic Profit
Residual Income
$1.03
$1.02
$1.05
76
ROIC Compounder
$0.5500
$0.5800
$0.6100
70
Growth Earnings
Growth-Adj P/E
$0.7200
$1.03
$1.35
67
Notify me when PIAHY reaches fair value
Put PIAHY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
52/100
Of which business quality 52 · Market factors (momentum, volatility) 10
Profitability
28
Margins and returns on capital today
Quality Growth
68
Are margins and returns improving?
Cashflow
54
Earnings quality: real cash, not paper profit
Fin. Strength
72
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
28
Calm price path (market factor)
Momentum
4
Price trend over the last 3–12 months (market factor)
52W Momentum
0
Distance to the 52-week high (market factor)
Net Issuance
0
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Start year 2020 (pandemic). Over 10 years: +34.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13.4% (2020) → 3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −7.8% a year for the price and +9.9% for the forecasts.
Forecast 2026 (sales)+12.1%
Forecast 2027 (sales)+13.8%
Projected 2028 (sales)+12.4%
Projected 2029 (sales)+10.9%
Projected 2030 (sales)+9.4%
PIAHY screens overvalued: fair value 30% below the price. Compare with Veeva Systems Inc →
Compare Ping An Healthcare and Technology Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $278.57 | $306.43 | +10% |
| Pro Medicus Limited PME | A$161.00 | A$84.62 | −47% |
| BrightSpring Health Services, Inc BTSG | $56.54 | $25.86 | −54% |
| Hinge Health, Inc HNGE | $95.57 | $51.25 | −46% |
| HealthEquity, Inc HQY | $88.44 | $97.28 | +10% |
| Waystar Holding WAY | $24.70 | $27.17 | +10% |
| Doximity, Inc DOCS | $26.35 | $31.41 | +19% |
| XtalPi Holdings 2228 | HK$7.75 | HK$1.50 | −81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,779 | ₹1,883 | +6% |
| Privia Health Group PRVA | $19.62 | $5.02 | −74% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Ping An Healthcare and Technology Company (PIAHY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.03 versus the last price from Sep 25, 2026 of $1.47, about −30% upside (overvalued).
What is the fair value of PIAHY?
Our model-based fair value for Ping An Healthcare and Technology Company is $1.03 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $1.47.
What is the quality score of PIAHY?
Ping An Healthcare and Technology Company has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ping An Healthcare and Technology Company (PIAHY)?
Our model-based price target is the fair value of $1.03 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $0.8600, optimistic scenario $1.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Ping An Healthcare and Technology Company stock forecast for 2026?
Our models put fair value at $1.03, about −30% upside versus the last price from Sep 25, 2026 of $1.47 (overvalued). Cautious scenario $0.8600, optimistic scenario $1.35. The calculation is refreshed regularly with new filings.
What is the revenue of Ping An Healthcare and Technology Company (PIAHY)?
Ping An Healthcare and Technology Company reported trailing-twelve-month revenue of about 5.5B CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into Ping An Healthcare and Technology Company (PIAHY)?
For today's price to be fair in a discounted-cash-flow model, Ping An Healthcare and Technology Company would have to grow free cash flow by -6.3 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of PIAHY use?
Our models discount Ping An Healthcare and Technology Company at 9.9 %: a base by market capitalisation (mid), damped by beta 1.08, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ping An Healthcare and Technology Company that is -6.3 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Ping An Healthcare and Technology Company (PIAHY) delivered so far?
Over the past 5 years revenue at Ping An Healthcare and Technology Company grew -5.0 % a year. The price currently implies -6.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ping An Healthcare and Technology Company (PIAHY) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Ping An Healthcare and Technology Company (-6.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ping An Healthcare and Technology Company (PIAHY)?
The free-cash-flow yield on the price is 3.85 %: that much free cash flow Ping An Healthcare and Technology Company produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ping An Healthcare and Technology Company (PIAHY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ping An Healthcare and Technology Company it is $1.03 per share (as of Sep 24, 2026), against a price of $1.47. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Ping An Healthcare and Technology Company stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PIAHY trades above its calculated fair value: price $1.47, fair value $1.03, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PIAHY?
No. The price is what the market pays today ($1.47); the fair value is what the company's own numbers justify ($1.03). For Ping An Healthcare and Technology Company the two are $0.4400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ping An Healthcare and Technology Company worth?
The market values Ping An Healthcare and Technology Company at about $3.2B (market capitalisation, as of Sep 24, 2026). Per share that is $1.47; our models calculate a fair value of $1.03 per share.
What do the bullish and bearish scenarios say about PIAHY?
Our models span a range for Ping An Healthcare and Technology Company: cautious scenario $0.8600, base $1.03, optimistic $1.35 per share (as of Sep 24, 2026, price $1.47). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is PIAHY from its 52-week high?
Ping An Healthcare and Technology Company trades at $1.47, about 70% below its 52-week high of $4.85 and at the low of $1.47 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $1.03 is for.
Which stocks are comparable to Ping An Healthcare and Technology Company?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ping An Healthcare and Technology Company stock attractive at the current price?
The data as of Sep 24, 2026: price $1.47, calculated fair value $1.03 (−30%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PIAHY calculated?
We run Ping An Healthcare and Technology Company through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ping An Healthcare and Technology Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ping An Healthcare and Technology Company (PIAHY)?
The latest price we hold is from Sep 25, 2026 and stands at $1.47. Our model-based fair value is $1.03, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ping An Healthcare and Technology Company right now?
The price sits above even our optimistic bull case ($1.35). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Ping An Healthcare and Technology Company
How large is the market capitalisation of Ping An Healthcare and Technology Company (PIAHY)?
The market capitalisation of Ping An Healthcare and Technology Company is $3.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Ping An Healthcare and Technology Company (PIAHY)?
The price-to-earnings ratio of Ping An Healthcare and Technology Company is 60.0 (as of Jun 22, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Ping An Healthcare and Technology Company (PIAHY)?
The price-to-sales ratio of Ping An Healthcare and Technology Company is 4.16 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ping An Healthcare and Technology Company (PIAHY)?
Earnings per share at Ping An Healthcare and Technology Company are $0.0500 (price ÷ EPS = P/E 60.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ping An Healthcare and Technology Company (PIAHY)?
The net margin of Ping An Healthcare and Technology Company is 6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ping An Healthcare and Technology Company (PIAHY)?
The return on equity (ROE) of Ping An Healthcare and Technology Company is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ping An Healthcare and Technology Company (PIAHY)?
On an EBIT basis the return on assets of Ping An Healthcare and Technology Company is −3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ping An Healthcare and Technology Company (PIAHY)?
The operating margin of Ping An Healthcare and Technology Company is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ping An Healthcare and Technology Company (PIAHY)?
Revenue at Ping An Healthcare and Technology Company is growing +9.3% versus a year earlier (3y avg −5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ping An Healthcare and Technology Company (PIAHY)?
Earnings per share at Ping An Healthcare and Technology Company are growing +378% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ping An Healthcare and Technology Company (PIAHY) hold?
Ping An Healthcare and Technology Company holds more cash than debt, 2.4B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.